Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue

Ewa Sierko; Marek Z. Wojtukiewicz; Lech Zimnoch; Walter Kisiel

doi:10.1160/TH09-06-0416

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 103(01): 198-204
DOI: 10.1160/TH09-06-0416

Cellular Proteolysis and Oncology

Schattauer GmbH

Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue

Authors

Ewa Sierko

¹Department of Oncology, Medical University, Bialystok, Poland

²Comprehensive Cancer Center, Bialystok, Poland
Marek Z. Wojtukiewicz

¹Department of Oncology, Medical University, Bialystok, Poland

²Comprehensive Cancer Center, Bialystok, Poland
Lech Zimnoch

³Medical Pathomorphology, Medical University, Bialystok, Poland
Walter Kisiel

⁴Department of Pathology, University of New Mexico, School of Medicine, Albuquerque, New Mexico, USA

Abstract

Summary

Activation of blood coagulation, a phenomenon frequently observed in breast and colon cancer patients, contributes to tumour progression. The principal initiator of blood coagulation activation in cancer patients is tissue factor (TF), while tissue factor pathway inhibitor (TFPI) is the main inhibitor of the TF-dependent pathway of blood coagulation. Previous immunohistochemical studies revealed no expression of TFPI in human cancer cells. The aim of the study was to evaluate the expression of TFPI protein and mRNA in breast and colon cancer tissues. A total of 108 cancer tissues (from primary tumours and metastatic lymph nodes) were obtained from 87 patients during surgical treatment. Immunohistochemical studies using a polyclonal anti-TFPI antibody were performed including a semiquantitative analysis. The in situ hybridisation method employed single-stranded DNA oligonucleotide (probe sequence: 5’Biotin-CCACCATACTTGAAACGTTCACACT-Biotin3’) directed against TFPI mRNA. Strong or medium expression of TFPI protein was observed in cancer cell bodies in all breast cancers and in most (39/66 cases) colon cancers examined. Weaker expression of TFPI was detected in cancer cells localised in lymph node metastatic foci of breast cancer. Endothelial cells were also TFPI-positive. TFPI mRNA was demonstrated in all cases of breast and in approximately 80% cases of colon cancer cells. TFPI mRNA and protein are present in association with colon and breast cancer cells, suggesting that the protein may play a role in cancer biology. The presence of TFPI in association with breast cancer cells localised in regional lymph nodes may indicate its role in lymphatic spread.

Keywords

Breast cancer - coagulation inhibitor - colon cancer - TFPI - tissue factor pathway inhibitor

Volltext

Referenzen

References
1 Falanga A, Rickles FR. Patophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-182.
2 Zacharski LR, Wojtukiewicz MZ, Costantini V. et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-116.
3 Wojtukiewicz MZ, Sierko E, Rak J. Contribution of hemostatic system to angio-genesis in cancer. Semin Thromb Hemost 2004; 30: 5-20.
4 Wojtukiewicz MZ, Sierko E, Kisiel W. The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost 2007; 33: 621-641.
5 Van Doormaal FF, Raskob GE, Davidson BL. et al. Treatment of thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009; 101: 762-769.
6 Toth B, Liebhardt S, Steinig K. et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008; 100: 663-669.
7 Haubold K, Rink M, Spath B. et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101: 1147-1155.
8 Novotny WF, Girard TJ, Miletich JP. et al. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837.
9 Bajaj MS, Kuppuswamy MN, Manepalli AN. et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 83: 1047-1052.
10 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-477.
11 Werling RW, Zacharski LR, Kisiel W. et al. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-369.
12 Kokawa T, Abumiya T, Kimura T. et al. Tissue factor pathway inhibitor activity in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 504-510.
13 Zhang J, Piro O, Lu L, Broze Jr. GJ. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108: 623-627.
14 Maroney SA, Mast AE. Expression of tissue factor inhibitor by endothelial cells and platelets. Transfus Apher Sci 2008; 38: 9-14.
15 Broze Jr. GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
16 Lindahl AK, Sandset PM, Abildgaard U. et al. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989; 155: 389-393.
17 Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59: 651-656.
18 Gerlach R, Scheuer T, Bohm M. et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res 2003; 25: 335-338.
19 Radziwon P, Schenk JF, Mazgajska K. et al. Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies [Article in Polish]. Pol Merkur Lekarski 2002; 13: 308-311.
20 Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res 2002; 105: 33-36.
21 Iversen LH, Okholm M, Thorlacius-Ussing OO. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease – a preliminary study. Thromb Haemost 1996; 76: 523-528.
22 Erman M, Abali H, Oran B. et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. Ann Oncol 2004; 15: 1622-1626.
23 Kurer MA. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 2007; 34: 221-224.
24 Pedersen AH, Nordfang O, Norris F. et al. Recombinant human extrinsic pathway inhibitor: Production, isoltion and characterization of its inhibitory activity on tissue factor initiated coagulation reactions. J Biol Chem 1990; 265: 16786-16793.
25 Hamamoto T, Yamamoto M, Nordfang O. et al. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). J Biol Chem 1993; 268: 8704-8710.
26 Sato Y, Mukai K, Watanabe S. et al. The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986; 125: 431-435.
27 Komminoth P, Werner M. Target and signal amplification: approaches to increase the sensitivity of in situ hybridization. Histochem Cell Biol 1997; 108: 325-333.
28 Kasprzak A, Zabel M, Wysocki J. et al. Detection of DNA, mRNA and early antigen of the human cytomegalovirus (HCMV) using Immunomax technique in autopsy material of children with intrauterine infection. Virchows Arch 2000; 437: 482-490.
29 Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for Immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologie 1987; 08: 138-140.
30 Wojtukiewicz MZ, Zacharski LR, Memoli VA. et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989; 62: 1062-1066.
31 Ueno T, Toi M, Koike M. et al. Tissue factor expression in breast cancer tissue: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-170.
32 Shigemori C, Wada H, Matsumoto K. et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1999; 274: 894-898.
33 Costantini V, Zacharski LR, Memoli VA. et al. Fibrinogen deposition without fibrin generation in primary human breast cancer tissue. Cancer Res 1991; 51: 349-353.
34 Versteeg HH, Spek CA, Richel DJ. et al. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004; 23: 410-417.
35 Jiang X, Bailly MA, Paneti TS. et al. Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2004; 02: 93-101.
36 Jiang X, Zhu S, Panetti TS. et al. Formation of tissue factor – factor VII – factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Thromb Haemost 2008; 100: 127-133.
37 Ruf W, Müller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 03: 379-384.
38 Wojtukiewicz MZ, Tang TG, Ben-Josef E. et al. Solid tumor cells express functional “tethered ligand” thrombin receptor. Cancer Res 1995; 55: 698-704.
39 Kataoka H, Uchino H, Asada Y. et al. Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and meta-static sublines to the liver. Int J Cancer 1997; 72: 878-884.
40 Hembrough TA, Swartz GM, Papathanassiu A. et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63: 2997-3000.
41 Fischer EG, Riewald M, Huang HY. et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999; 104: 1213-1221.
42 Ruf W, Seftor EA, Petrovan RJ. et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003; 63: 5381-5389.
43 Provencal M, Michaud M, Beaulieu E. et al. Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost 2008; 99: 576-585.
44 Amirkhoshravi A, Meyer T, Chang J-Y. et al. Tissue factor pathway inhibitor reduces experimental lung metastases of B16 melanoma. Thromb Haemost 2002; 87: 930-936.
45 Bromberg ME, Konigsberg WH, Madison JF. et al. Tissue factor promotes meta-stasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-8209.
46 Müller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis. J Clin Invest 1998; 101: 1372-1378.
47 Honn KV, Tang GT, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992; 18: 392-415.